BPC‑157 (Body Protection Compound‑157) Peptide Profile
Overview:
BPC‑157 is a synthetic pentadecapeptide (15 amino acids) derived from a naturally occurring protective protein found in human gastric juice. It is often referred to as Body Protection Compound‑157 and has been widely studied in preclinical (animal) research for its potential tissue‑protective, regenerative, anti‑inflammatory, and angiogenic effects. Despite promising preclinical findings, BPC‑157 is not approved by the FDA or other major regulatory agencies for clinical use in humans, and robust human clinical evidence remains very limited. It is banned by the World Anti‑Doping Agency (WADA) as an unapproved performance‑enhancing substance due to its potential effects on tissue repair and recovery. (Wikipedia)
Mechanism of Action:
BPC‑157 appears to exert effects through multiple interconnected pathways: it promotes angiogenesis (formation of new blood vessels) via activation of VEGF‑related signaling, enhances cell migration and proliferation important for tissue repair, modulates inflammatory responses, and may up‑regulate growth factor receptors such as the growth hormone receptor in fibroblasts. These mechanisms contribute to improved delivery of nutrients and oxygen to injured tissues and support structural recovery. (Wikipedia)
Preclinical and Limited Human Findings:
In animal models, BPC‑157 has shown accelerated healing of tendons, ligaments, muscles, bone, and GI tissues, and cytoprotective and anti‑inflammatory effects. Human safety data are scarce, though a small pilot infusion study reported tolerability of doses up to 20 mg in two healthy adults without adverse biomarkers; confirmation in larger cohorts is needed. (PubMed)
Regulatory & Safety Notes:
Health authorities discourage use outside research settings due to lack of clinical approval and safety data, and because products sold online are often unregulated research chemicals with contamination or mislabeling risks. Theoretical concerns include angiogenesis‑related cancer risk due to new blood vessel formation, though data are very limited. (Wikipedia)
Typical Experimental Dosing Chart (Preclinical / Anecdotal):
| Protocol | Dose | Frequency | Route | Notes |
| Research models | 10–500 μg/kg | 1–2×/day | IP/SC/IM/IV | Animal studies; human relevance unproven (Wikipedia) |
| Human pilot infusion* | 10–20 mg total | Single or short course | IV | Tolerability shown in 2 adults; safety not established (PubMed) |
*Not a clinical recommendation.
References (APA):
BPC‑157. (n.d.). Wikipedia. https://en.wikipedia.org/wiki/BPC-157 (Wikipedia)
Jóźwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and possible medical application of the BPC‑157 peptide: Literature and patent review. Pharmaceuticals. (MDPI)
Vasireddi, N., et al. (2025). Emerging use of BPC‑157 in orthopaedic sports medicine: A systematic review. HSS Journal. (SAGE Journals)
Safety of intravenous infusion of BPC‑157 in humans: A pilot study. (2025). PubMed. (PubMed)
BPC‑157: Experimental peptide prohibited. (2025). USADA. (NPC Hello)
